Topotecan (Hycamtin): FDA Approval, Licensing in Türkiye, and Reimbursement Status

• FDA Approval: Yes (first approval date: May 28, 1996)
• Trade Name: Hycamtin
• Active Ingredient: Topotecan
• Administration: Intravenous (IV injection) and oral capsules
• Class: Topoisomerase I inhibitor
• Category: Cytotoxic chemotherapy agent
• Manufacturer: GlaxoSmithKline (original); various generic manufacturers
• Distribution in Türkiye: GlaxoSmithKline Türkiye and equivalent generic companies
• Cancers for Which It Is Approved: Ovarian cancer, small cell lung cancer (SCLC), and cervical cancer (advanced or recurrent). It may also be used off-label in some breast cancer cases.

What Is Topotecan (Hycamtin) and How Does It Work?

Topotecan is a chemotherapy medicine used particularly for certain advanced cancers. To stop cell division, it inhibits topoisomerase I, an enzyme acting on DNA that is essential for normal DNA function and repair. Inhibiting it damages cancer cell DNA and causes cell death. It is used particularly for ovarian, small cell lung, and cervical cancers.

How Does It Work?

• Topotecan targets topoisomerase I, an enzyme that regulates structural tension during DNA replication. It temporarily cuts one strand of the DNA double helix, relieving tension and allowing DNA to unwind. It then repairs the breaks to restore DNA integrity.
• Topotecan binds to the temporary complex formed between topoisomerase I and DNA, preventing the enzyme from rejoining (re-ligating) single-strand breaks. Unrepaired breaks consequently accumulate.
• When cells attempt to continue DNA replication, replication forks cannot move through these unstable regions, resulting in double-strand DNA breaks. These highly dangerous lesions trigger apoptosis (programmed cell death) if they cannot be repaired.
• Topotecan is particularly effective in rapidly dividing cancer cells, where DNA synthesis is more active and replication damage may be sufficient to halt the cell. Because normal cells may be similarly affected, careful dose adjustment is required.

FDA (United States Food and Drug Administration) Approval History

• May 28, 1996: Topotecan received FDA approval under the brand name Hycamtin for advanced ovarian cancer.
• October 30, 1998: The FDA approved topotecan for small cell lung cancer (SCLC).
• June 14, 2006: The FDA approved topotecan combined with cisplatin for cervical cancer.
• October 15, 2007: The FDA approved oral topotecan capsules for recurrent small cell lung cancer (SCLC).

Licensing in Türkiye

Topotecan is licensed in Türkiye and used to treat certain cancers.

Therapeutic Indications

• Metastatic ovarian cancer after failure of first-line treatment or subsequent chemotherapy.
• Relapsed small cell lung cancer when retreatment with the first-line regimen is considered unsuitable.
• Topotecan combined with cisplatin is indicated for cervical cancer recurring after radiotherapy and for stage IVB disease. After previous cisplatin exposure, a prolonged treatment-free interval is required to confirm suitability for this combination.

Is It Reimbursed?

SGK (Social Security Institution) reimburses topotecan in the following treatment situations:

• Advanced metastatic ovarian cancer that has not responded to first-line treatment or has progressed after treatment.
• Small cell lung cancer: Indicated for patients sensitive to first-line chemotherapy whose disease did not progress for at least 60 days after treatment and subsequently relapsed.

Price: Topotecan 4 mg vial: 3778.31 TL

Mechanisms of Resistance

• Reduced or altered topoisomerase I: Topotecan acts by binding the temporary complex between topoisomerase I and DNA. Some cancer cells reduce enzyme production or alter its structure, preventing binding. Topotecan then fails to damage DNA and becomes ineffective.
• Drug efflux (pump activity): Cancer cells may increase membrane transporters such as P-glycoprotein (P-gp), expelling the drug. This lowers intracellular topotecan and reduces its effect. Such resistance often accompanies multidrug resistance (MDR).
• Increased DNA repair: Topotecan triggers cell death through DNA damage. Some cells strengthen their repair mechanisms and rapidly repair the damage, weakening its lethal effects.
• Changes in cell cycle regulatory proteins: Topotecan arrests the cell cycle in response to DNA damage. Mutations in regulatory proteins such as p53 may prevent cells from recognizing damage and stopping, contributing to resistance.

Absorption

Topotecan can be administered intravenously (IV) or orally. The IV formulation enters blood directly, so absorption is not an issue. Oral absorption from the intestine is rapid, but bioavailability is moderate. Absorption varies between individuals and may be slightly affected by food.

Distribution

Topotecan distributes into many tissues. Its high volume of distribution indicates extensive distribution into extracellular fluid and tissues. It crosses the blood–brain barrier to a limited extent but may reach therapeutic concentrations in some central nervous system tumors. Low plasma protein binding leaves a high proportion of active drug circulating unbound.

Metabolism

Topotecan may exist in two chemical forms: an active form (open lactam ring) and an inactive form (closed lactam ring). Most metabolism occurs through extrahepatic mechanisms, with no substantial metabolism by liver cytochrome P450 enzymes. Liver dysfunction may therefore have limited pharmacokinetic effects. Renal elimination nevertheless plays an important role. Some drug is excreted unchanged through the kidneys, so reduced kidney function may lower clearance and require dose adjustment.

Dose Range

Ovarian Cancer – IV Administration

• Dose: 1.5 mg/m²
• Administration: IV infusion over 30 minutes
• Schedule: 5 consecutive days followed by a 3-week break (21-day cycles)
• Generally preferred after prior platinum-based treatment when disease has progressed.

Small Cell Lung Cancer – IV Administration

• Dose: 1.5 mg/m²
• Administration: IV infusion over 30 minutes
• Schedule: For 5 days, repeated every 21 days
• Generally used after relapse following first-line treatment.
• Alternative regimen (oral formulation):
• Oral dose: 2.3 mg/m²
• Schedule: For 5 days, every 21 days
• Preferred when IV treatment is unsuitable.

Cervical Cancer – Combination Treatment

• Dose: 0.75 mg/m²
• Administration: IV infusion over 30 minutes
• Schedule: Once weekly for 3 weeks, with cisplatin
• Used for advanced or recurrent cervical cancer.

Drug Interactions

• Renally eliminated medicines: Topotecan is eliminated largely through the kidneys. Combining it with medicines affecting kidney function or other renally eliminated drugs may slow elimination, causing accumulation and increased toxicity. Particular caution is needed with nephrotoxic medicines such as aminoglycoside antibiotics or platinum agents, including cisplatin.
• Medicines increasing bone marrow suppression: Topotecan suppresses bone marrow. Other chemotherapy or myelosuppressive medicines used concurrently may intensify this effect, causing severe neutropenia, anemia, or thrombocytopenia. Blood counts require close monitoring with such combinations.
•  Oral topotecan and acid-suppressing medicines: Medicines that change gastric pH, such as proton pump inhibitors or antacids, may affect absorption of oral topotecan. Concurrent use may reduce bioavailability and expected effectiveness.
• P-glycoprotein: Topotecan is affected by transport proteins called P-glycoprotein (P-gp), which expel some medicines from cells. P-gp inhibitors or inducers may alter intracellular topotecan levels, although this effect is more limited than for medicines such as paclitaxel.

Precautions

• Bone marrow suppression (myelosuppression): Topotecan may suppress white blood cells (neutrophils), red blood cells (erythrocytes), and platelets. Monitor complete blood counts regularly before and during treatment. Severe neutropenia increases infection risk and may require dose reduction or treatment interruption.
• Infection risk: Immune suppression makes patients more vulnerable to infection. High fever, chills, sore throat, or other infection symptoms require immediate assessment.
• Kidney function: Topotecan is eliminated largely through the kidneys. Impairment may cause accumulation and increased adverse reactions. Calculate creatinine clearance before treatment and adjust the dose if needed.
• Liver impairment: Although elimination is mainly renal, liver dysfunction may affect metabolism. Use cautiously in severe liver impairment and monitor liver enzymes.
• Gastrointestinal adverse reactions: Nausea, vomiting, and diarrhea are common. Severe symptoms require supportive care to prevent dehydration. Maintain oral hygiene because mouth sores may also develop.
• Pregnancy and breastfeeding: Topotecan must not be used during pregnancy because it can harm the unborn baby. It is also not recommended during breastfeeding because of possible passage into milk. Women of reproductive age should use effective contraception throughout treatment.
• Older patients: Kidney function may naturally decline with age. Dose adjustment and greater vigilance for adverse reactions may therefore be necessary.
• Allergic reactions: Rare hypersensitivity may occur, including rash, itching, or breathlessness. Stop the drug and provide appropriate treatment if these reactions occur.

Adverse Reactions

The most frequently reported reactions to topotecan (Hycamtin®) in clinical trials are:

• Low white blood cells (leukopenia): 61–88%
• Low platelets (thrombocytopenia): 38–58%
• Hair loss (alopecia): 36%
• Low red blood cells (anemia): 23–42%
• Fatigue: 4–26%
• Reduced appetite: 5–19%
• Bacterial, viral, or fungal infection: 14–18%
• Oral and mucosal inflammation (mucositis): 14%
• Diarrhea: 6–12%
• Breathlessness: 3–8%
• Vomiting: 2–24%
• Weakness: 5%
• Nausea: 4%
• Neutropenic fever: 3%
• Fever: 2–4%